UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2021
Commission File Number: 001-38178
Zealand Pharma A/S
(Translation of registrant’s name into English)
Sydmarken 11
2860 Søborg (Copenhagen)
Denmark
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: x Form 20-F ¨ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Filed as Exhibit 99.1 to this Report on Form 6-K are the audited consolidated financial statements of Valeritas Holdings, Inc. (“Valeritas”) as of December 31, 2019 and for the year then ended and the related notes.
Filed as Exhibit 99.2 to this Report on Form 6-K are the unaudited consolidated financial statements of Valeritas as of March 31, 2020 and for the three months then ended and the related notes.
Filed as Exhibit 99.3 to this Report on Form 6-K are the unaudited pro forma condensed combined financial information for the year ended December 31, 2019 and the nine months ended September 30, 2020 combining the historical financial information of the registrant and Valeritas in connection with the acquisition by the registrant of substantially all assets of Valeritas in April 2020.
Exhibits 23.1, 99.1, 99.2 and 99.3 to this Report on Form 6-K are hereby expressly incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-230654) filed with the Securities and Exchange Commission on April 1, 2019.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Zealand Pharma A/S | ||
Date: March 10, 2021 | By: | /s/ Matthew Dallas |
Name Matthew Dallas | ||
Title: Chief Financial Officer |